Recruiting
Phase 3

Lenalidomide & Dexamethasone

Sponsor:

ECOG-ACRIN Cancer Research Group

Code:

NCT03937635

Conditions

Smoldering Plasma Cell Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Daratumumab

Dexamethasone

Lenalidomide

Quality-of-Life Assessment

Questionnaire Administration

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by ECOG-ACRIN Cancer Research Group on 2024-08-09.